This finding motivates the development of combination therapy for colorectal cancer by co-targeting both KRASG12C and EGFR.486,487 Because EGFR/SHP2 signaling is a well-known upstream stimulus for activation of KRASG12C, co-targeting EGFR/SHP2 signaling and KRASG12C is an attractive strategy. This evidence concerns the gene EGFR and colorectal cancer.